- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07468162
Characteristic Electroencephalogram of General Anesthesia
March 9, 2026 updated by: Zhu Weiliu, First Affiliated Hospital of Zhejiang University
Analysis of the Characteristic Electroencephalogram of Patients Undergoing Orthopedic Surgery During the Induction of General Anesthesia and the Unconscious State and Recovery Period With Electroencephalogram Monitoring Device
Patients were enrolled according to predefined inclusion and exclusion criteria.
Following surgical admission, standard monitoring was initiated, including continuous assessment of heart rate, blood pressure, electrocardiogram (ECG), and peripheral capillary oxygen saturation (SpO₂).
A peripheral intravenous line was established.
Bispectral index (BIS) monitoring was performed continuously using a BIS monitor to assess frontal lobe electroencephalographic activity.
Based on the type of surgical procedure, regional nerve block was administered.
Upon confirmation of adequate block efficacy, patients were assigned to treatment groups according to sealed envelope randomization, and corresponding intravenous sedative regimens were initiated.
Sedative induction agents were administered as follows: Group A received remimazolam at 0.08 mg/kg; Group B received dexmedetomidine at 1 μg/kg over 10 minutes; Group C received midazolam at 0.05 mg/kg.
Maintenance infusions were as follows: Group A received remimazolam at 1 mg/kg·h; Group B received dexmedetomidine at 0.2-0.7 μg/kg·h; for Group C, if consciousness was not sufficiently suppressed with the initial dose, midazolam was supplemented in increments of 0.01 mg/kg, not exceeding a total dose of 0.1 mg/kg.
Following induction, sedation depth was assessed every 2 minutes using the Observer's Assessment of Alertness/Sedation (OAA/S) scale, with auditory stimulation applied every 30 seconds until the patient no longer responded.
The time to loss of response to auditory stimuli and the time to loss of consciousness were recorded.
Surgical intervention was then performed.
Ten minutes prior to anticipated completion of surgery, sedative infusion was discontinued.
Sedation depth was reassessed every 2 minutes using the OAA/S scale, with repeated auditory stimulation every 30 seconds to determine the time to return of response and time to recovery of consciousness.
If the patient had not achieved an OAA/S score of 5 within 30 minutes after discontinuation of sedation, flumazenil was administered as a reversal agent.
Once the OAA/S score reached 5 or spontaneous responses to auditory stimuli were observed-indicating transition back to a responsive state-and complete electroencephalographic data had been collected, no further intervention was required.
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
48
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: weiliu Zhu, Master
- Phone Number: +86 15858287662
- Email: zhuweiliu1988@163.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Patients undergoing elective orthopedic surgery under nerve block combined with intravenous anesthesia
Description
Inclusion Criteria:
- Age: 20 - 60 years old. BMI: 18 ≤ BMI ≤ 24 kg/m2. Right-handed. ASA classification: I - II. Patients scheduled for extremity surgery of upper and lower limbs and undergoing nerve block, those who understand and sign the informed consent form, and those receiving non-endotracheal general anesthesia with remimazolam or dexmedetomidine or midazolam, with Mallampati classification: I - II.
Exclusion Criteria:
- Skin infection at the site of nerve block puncture; history of smoking and alcohol abuse, history of brain surgery, history of cerebral infarction, mental and neurological disorders (MMSE < 18, 3D-CAM positive), history of taking any psychotropic or opioid drugs within 2 weeks, hearing impairment, cardiovascular disease, expected difficulty in airway management or sleep apnea syndrome, drug (including those with a history of allergic reaction to the test drug or contraindications for use) or food allergies, pregnant or lactating patients, patients or family members who refuse to participate, and those who refuse to undergo nerve block.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
sedation of remimazolam
Electroencephalogram changes under moderate deep sedation induced by remimazolam
|
Electroencephalogram changes under moderate deep sedation
|
|
sedation of dexmedetomidine
Electroencephalogram changes under moderate deep sedation induced by dexmedetomidine
|
Electroencephalogram changes under moderate deep sedation
|
|
sedation of midazolam
Electroencephalogram changes under moderate deep sedation induced by midazolam
|
Electroencephalogram changes under moderate deep sedation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Electroencephalogram changes during the perioperative period
Time Frame: From the date of random grouping until the end of the surgery
|
Power changes in α and β bands of electroencephalogram during the perioperative period
|
From the date of random grouping until the end of the surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Schuttler J, Eisenried A, Lerch M, Fechner J, Jeleazcov C, Ihmsen H. Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part I. Pharmacokinetics and Clinical Pharmacodynamics. Anesthesiology. 2020 Apr;132(4):636-651. doi: 10.1097/ALN.0000000000003103.
- Zhang H, Zhou QQ, Chen H, Hu XQ, Li WG, Bai Y, Han JX, Wang Y, Liang ZH, Chen D, Cong FY, Yan JQ, Li XL. The applied principles of EEG analysis methods in neuroscience and clinical neurology. Mil Med Res. 2023 Dec 19;10(1):67. doi: 10.1186/s40779-023-00502-7.
- Schartner M, Seth A, Noirhomme Q, Boly M, Bruno MA, Laureys S, Barrett A. Complexity of Multi-Dimensional Spontaneous EEG Decreases during Propofol Induced General Anaesthesia. PLoS One. 2015 Aug 7;10(8):e0133532. doi: 10.1371/journal.pone.0133532. eCollection 2015.
- Valizadeh SA, Riener R, Elmer S, Jancke L. Decrypting the electrophysiological individuality of the human brain: Identification of individuals based on resting-state EEG activity. Neuroimage. 2019 Aug 15;197:470-481. doi: 10.1016/j.neuroimage.2019.04.005. Epub 2019 Apr 9.
- White-Dzuro GA, Du A, Brown EN, Akeju O, Peterfreund RA. The Effect of Midazolam Induction on Frontal Electroencephalogram Power. Anesth Analg. 2025 Nov 1;141(5):1185-1187. doi: 10.1213/ANE.0000000000007556. Epub 2025 May 23. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 20, 2026
Primary Completion (Estimated)
January 12, 2028
Study Completion (Estimated)
January 12, 2028
Study Registration Dates
First Submitted
January 8, 2026
First Submitted That Met QC Criteria
March 9, 2026
First Posted (Actual)
March 12, 2026
Study Record Updates
Last Update Posted (Actual)
March 12, 2026
Last Update Submitted That Met QC Criteria
March 9, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- IIT20251166B-R2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Orthopedic Surgery
-
Rigshospitalet, DenmarkThe Danish Medical Research Council; Oberstinde Kirsten Jensa la Cours FoundationCompleted
-
University Hospital, GrenobleCompletedOrthopedic SurgeryFrance
-
Centre Hospitalier Universitaire de Saint EtienneCompletedOrthopedic SurgeryFrance
-
Yonsei UniversityUnknownOrthopedic Surgery-lower Leg SurgeryKorea, Republic of
-
University Hospital, LimogesCompleted
-
University Hospital, MontpellierCompleted
-
Groupe Hospitalier Paris Saint JosephWithdrawn
-
University Hospital, MontpellierUnknownOrthopedic SurgeryFrance
-
Yonsei UniversityRecruitingOrthopedic SurgeryKorea, Republic of
-
Muhammad Aamir LatifCompleted
Clinical Trials on After the use of sedative drugs, the changes in the electroencephalogram (EEG) spectrum were observed with an EEG monitor
-
Medical University of SilesiaCompletedNon ST Elevation Myocardial InfarctionUnited States, Poland
-
Memorial Sloan Kettering Cancer CenterPfizer; Dana-Farber Cancer Institute; University of Pittsburgh; University of VirginiaCompletedNeurofibromatosis | Meningioma | CNS Cancer | Hemangioblastoma | Intracranial HemangiopericytomaUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedNon-Hodgkin's Lymphoma | CNS Lymphoma | CNS Brain CancerUnited States